Announcements Trials
Browse Landscape

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 350Stomach Neoplasms 31Neoplasm Metastasis 30Breast Neoplasms, Male 25Neoplasms 16Inflammatory Breast Neoplasms 12Brain Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Esophageal Neoplasms 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Adenocarcinoma 5Sarcoma 4Lung Neoplasms 4HER2-positive Breast Cancer 4Endometrial Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Head and Neck Neoplasms 3HER2 Positive Breast Cancer 3Cardiotoxicity 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3

Interventions

Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HER2+ Breast Cancer × Trastuzumab × Clear all
NCT05931042 2023-07-05

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Rawalpindi Medical College

Completed
1,209 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡